MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON
ROOM: WREN
FRIDAY, APRIL 29TH, 2016 – 8:00 AM – 12:00 PM

CHAIR: M. MCKENZIE
SENIOR INVESTIGATOR: WENDY PARULEKAR
STUDY COORDINATOR: ALEXANDER MONTENEGRO

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
− To understand and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
− To review recent developments in the understanding of molecular biology of cancers treated with radiotherapy.
− To update, review, and discuss recent results of clinical studies involving radiotherapy conducted by the Canadian Cancer Trials Group or national/international collaborators.
− To provide mentoring opportunities for investigators new to clinical trial research.
− To understand and apply new clinical trial methodologies in the field of clinical research.

8:00 am Welcome M. McKenzie

CCTG Led Closed trials
8:05 am HDR brachytherapy in intermediate risk CaP. PR.15 E. Vigneault

CCTG Led Open trials
8:15 am Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. HE.1 L. Dawson
8:25 am SBRT vs. conventional palliative radiotherapy for spinal metastases. SC.24 A. Sahgal

CCTG Intergroup Open trials
8:35 am Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. GA.1 R. Wong / J. Ringash
8:45 am Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. CEC.5 C. Chung

continued on next page …
**Updates in CCTG approved studies:**

8:55 am  Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer.  **PR.19**  
L. Hathout

9:05 am  Precision radiotherapy for oligometastatic NSCLC (PROMISE-NSCLC): a randomized phase II study.  **BR.35**  
P. Cheung

**Updates on previous discussed proposals**

9:15 am  Randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer.  **NRG-HN002**  
J. Waldron

9:25 am  Accelerated chemo-radiotherapy with/without nimorazole in HPV/p16-ve squamous cell head and neck cancer.  **EORTC 1219/DAHANCA-29**  
J. Waldron

9:35 am  Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).  **NRG-HN001**  
J. Waldron

9:45 am  Research platform for studies in oligometastatic disease.  
R. Wong

9:55 am  Postoperative adjuvant IMRT following cystectomy for T3/pT4 urothelial bladder cancer.  **NRG-GU001 on behalf of L. Eapen**  
M. McKenzie

10:05 am  Coffee Break

**New Study proposals**

10:20 am  Phase IIR of Immunotherapy +/- Stereotactic Body Radiotherapy for Metastatic Soft Tissue Sarcoma  
P. Wong

10:30 am  A randomized phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell carcinoma of the head and neck.  **EORTC-1601-HNCG**  
J. Waldron

10:40 am  A Randomized Phase II Trial to Assess the Efficacy of Hippocampal-Avoidance Prophylactic Cranial Irradiation in stage III/IV EGFR-mutant and ALK-rearranged NSCLC  
A. Brade

10:50 am  **PRIME Study** - Prevention and intervention for metabolic syndrome  
N. Usmani

11:00 am  **PCS VI**: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Standard Pelvic Radiation Therapy followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate  
T. Niazi

11:10 am  **PCS VIII**: The predictive value of coexisting TMPRSS2-ERG gene fusion and PTEN deletion in prostate cancer patients with biochemical failure status post salvage or radical radiation therapy  
T. Niazi

11:20 am  **PCS IX**: The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial  
T. Niazi

11:30 am  Chemoetherapy and radiotherapy for serous endometrial cancer  
A. Fyles

11:40 am  **Activities of the Radiation Oncology Quality Assurance Committee.**  
A. Nichol

12:00 pm  Meeting adjourned.